OS Therapies Net Worth
OS Therapies Net Worth Breakdown | OSTX |
OS Therapies Net Worth Analysis
OS Therapies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including OS Therapies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of OS Therapies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform OS Therapies' net worth analysis. One common approach is to calculate OS Therapies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares OS Therapies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing OS Therapies' net worth. This approach calculates the present value of OS Therapies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of OS Therapies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate OS Therapies' net worth. This involves comparing OS Therapies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into OS Therapies' net worth relative to its peers.
Enterprise Value |
|
To determine if OS Therapies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding OS Therapies' net worth research are outlined below:
| OS Therapies is way too risky over 90 days horizon | |
| OS Therapies appears to be risky and price may revert if volatility continues | |
| OS Therapies has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| OS Therapies generates negative cash flow from operations | |
| OS Therapies has a frail financial position based on the latest SEC disclosures | |
| About 25.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire |
OS Therapies Target Price Consensus
OSTX target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. OS Therapies' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most OSTX analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand OSTX stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of OS Therapies, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationOS Therapies Target Price Projection
OS Therapies' current and average target prices are 4.16 and 15.00, respectively. The current price of OS Therapies is the price at which OS Therapies Incorporated is currently trading. On the other hand, OS Therapies' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On OS Therapies Target Price
Follow OS Therapies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.14 M.Market Cap |
|
Project OS Therapies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (11.23) | (11.79) | |
| Return On Capital Employed | 0.21 | 0.20 | |
| Return On Assets | (11.23) | (11.79) | |
| Return On Equity | 0.29 | 0.26 |
When accessing OS Therapies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures OS Therapies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of OS Therapies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in OS Therapies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OS Therapies Incorporated. Check OS Therapies' Beneish M Score to see the likelihood of OS Therapies' management manipulating its earnings.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OS Therapies insiders, such as employees or executives, is commonly permitted as long as it does not rely on OS Therapies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OS Therapies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mckean-dieser Avril Suzette over two months ago Insider Trading | ||
Mckean-dieser Avril Suzette over two months ago Insider Trading | ||
Ciccio John over three months ago Acquisition by Ciccio John of 266306 shares of OS THERAPIES at 75000.0 subject to Rule 16b-3 | ||
Search Theodore F. over three months ago Acquisition by Search Theodore F. of 30264 shares of OS THERAPIES at 50000.0 subject to Rule 16b-3 | ||
Search Theodore F. over three months ago Acquisition by Search Theodore F. of 101765 shares of OS THERAPIES at 25000.0 subject to Rule 16b-3 | ||
Search Theodore F. over three months ago Acquisition by Search Theodore F. of 30264 shares of OS THERAPIES at 50000.0 subject to Rule 16b-3 | ||
Ciccio John over three months ago Acquisition by Ciccio John of 101765 shares of OS THERAPIES at 25000.0 subject to Rule 16b-3 | ||
Acevedo Christopher P. over three months ago Disposition of tradable shares by Acevedo Christopher P. of OS THERAPIES subject to Rule 16b-3 |
OS Therapies Corporate Filings
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of January 2025 Other Reports | ViewVerify | |
| 27th of November 2024 Other Reports | ViewVerify | |
10Q | 15th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
OS Therapies Earnings per Share Projection vs Actual
OS Therapies Corporate Management
| Jack Doll | Chief Staff | Profile | |
| Robert Petit | Chief Officer | Profile | |
| Christopher Acevedo | Chief Officer | Profile | |
| Gerald Commissiong | Chief Officer | Profile |
Additional Tools for OSTX Stock Analysis
When running OS Therapies' price analysis, check to measure OS Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OS Therapies is operating at the current time. Most of OS Therapies' value examination focuses on studying past and present price action to predict the probability of OS Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OS Therapies' price. Additionally, you may evaluate how the addition of OS Therapies to your portfolios can decrease your overall portfolio volatility.